US · DNTH · BIOTECHNOLOGY
Dianthus Therapeutics, Inc. (DNTH) intrinsic value and stock valuation
$84.55as of 2026-11-21 · Mkt cap 4.7B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Dianthus Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values DNTH with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from DNTH’s statements →
Dianthus Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M |
| Operating income | -$-177.93M | -$-101.86M | -$-48.17M | -$-29.7M | -$-13.09M |
| Net income | -$-162.34M | -$-84.97M | -$-43.55M | -$-28.48M | -$-13.11M |
| EPSd | -$-4.3M | -$-2.55M | -$-8.46M | -$-7.59M | -$-3.82M |
| Operating cash flow | -$-129.06M | -$-78.18M | -$-36.86M | -$-29.07M | -$-59.53M |
| Capital expenditure | -$-210K | -$-100K | -$-110K | -$-140K | -$-1.26M |
| Free cash flow | -$-129.27M | -$-78.28M | -$-36.97M | -$-29.21M | -$-60.8M |
| Total assets | $530.9M | $374M | $179.4M | $83.1M | $189.9M |
| Total debt | $1.39M | $1.49M | $580K | $790K | $0.00 |
| Net debt | -$-49.7M | -$-21.3M | -$-131.74M | -$-14.58M | -$-131.65M |
| Total equity | $493.4M | $352.5M | $168.9M | $73.7M | $172.7M |
| Cash and short-term investments | $404.3M | $275.2M | $173.7M | $75.5M | $176.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M |
| Research and development expenses | $145.6M | $83.1M | $32.8M | $29.4M | $12.6M |
| Selling, general and administrative expenses | $34.3M | $25M | $18.2M | $6.74M | $1.96M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $180M | $108.1M | $51M | $36.1M | $14.6M |
| Cost and expenses | $180M | $108.1M | $51M | $36.1M | $14.6M |
| Interest income | $16.1M | $17.4M | $4.76M | $1.15M | $100K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $430K | $410K | $350K | $150K | $2.02M |
| Ebitda | -$-161.91M | -$-84.56M | -$-43.2M | -$-28.33M | -$-11.09M |
| Operating income | -$-177.93M | -$-101.86M | -$-48.17M | -$-29.7M | -$-13.09M |
| Total other income/expenses, net | $15.6M | $16.9M | $4.62M | $1.23M | -$-20K |
| Income before tax | -$-162.34M | -$-84.97M | -$-43.55M | -$-28.48M | -$-13.11M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-162.34M | -$-84.97M | -$-43.55M | -$-28.48M | -$-13.11M |
| Weighted average shares outstanding | $37.8M | $33.3M | $5.15M | $3.75M | $3.43M |
| Weighted average diluted shares outstanding | $37.8M | $33.3M | $5.15M | $3.75M | $3.43M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $404.3M | $275.2M | $173.7M | $75.5M | $176.9M |
| Net receivables | $100K | $810K | $480K | $5.64M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $409.4M | $280.9M | $177.5M | $82M | $180.7M |
| Property, plant and equipment, net | $1.63M | $1.75M | $800K | $960K | $7.46M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $110.1M | $81.7M | $0.00 | $0.00 | $1.78M |
| Total non-current assets | $121.5M | $93.1M | $1.95M | $1.08M | $9.24M |
| Total assets | $530.9M | $374M | $179.4M | $83.1M | $189.9M |
| Accounts payable | $9.72M | $4.58M | $2.61M | $1.17M | $3.04M |
| Short-term debt | $370K | $320K | $420K | $350K | $0.00 |
| Deferred revenue | $1.19M | $480K | $100K | $100K | $0.00 |
| Total current liabilities | $30.7M | $18.5M | $9.63M | $8.22M | $10.9M |
| Long-term debt | $1.02M | $1.17M | $170K | $440K | $0.00 |
| Deferred revenue, non-current | $5.77M | $1.91M | $740K | $790K | $0.00 |
| Total non-current liabilities | $6.79M | $3.08M | $900K | $1.23M | $6.4M |
| Capital lease obligations | $370K | $1.49M | $580K | $790K | $0.00 |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.45M | $17.3M |
| Common stock | $40K | $30K | $10K | $0.00 | $60K |
| Retained earnings | -$-336.73M | -$-174.39M | -$-89.42M | -$-45.87M | -$-325.57M |
| Accumulated other comprehensive income (loss) | $490K | $110K | $50K | -$-160K | -$-30K |
| Total equity | $493.4M | $352.5M | $168.9M | $73.7M | $172.7M |
| Total investments | $463.3M | $334.2M | $41.4M | $60.1M | $47.1M |
| Total debt | $1.39M | $1.49M | $580K | $790K | $0.00 |
| Net debt | -$-49.7M | -$-21.3M | -$-131.74M | -$-14.58M | -$-131.65M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-162.34M | -$-84.97M | -$-43.55M | -$-28.48M | -$-71.14M |
| Depreciation and amortization | $430K | $410K | $350K | $150K | $2.02M |
| Stock-based compensation | $22.8M | $12.9M | $2.9M | $1.52M | $0.00 |
| Change in working capital | $16.7M | -$-350K | $4.86M | -$-1.65M | -$-1.53M |
| Accounts receivable | $760K | $0.00 | $5.16M | -$-4.16M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $11.3M | $8.19M | $660K | $2.28M | -$-720K |
| Net cash provided by operating activities | -$-129.06M | -$-78.18M | -$-36.86M | -$-29.07M | -$-59.53M |
| Investments in property, plant and equipment | -$-210K | -$-100K | -$-110K | -$-140K | -$-1.26M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-122.83M | -$-286.81M | $20.3M | -$-59.82M | $43.4M |
| Common stock issued | $280.1M | $269.2M | $72M | $0.00 | $89.6M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $280.1M | $255.6M | $133.6M | $96.7M | $89.6M |
| Net change in cash | $28.2M | -$-109.37M | $117M | $7.79M | $73.5M |
| Cash at end of period | $51.3M | $23M | $132.4M | $15.4M | $131.7M |
| Operating cash flow | -$-129.06M | -$-78.18M | -$-36.86M | -$-29.07M | -$-59.53M |
| Capital expenditure | -$-210K | -$-100K | -$-110K | -$-140K | -$-1.26M |
| Free cash flow | -$-129.27M | -$-78.28M | -$-36.97M | -$-29.21M | -$-60.8M |
Line items
Line items
Line items
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- CEO
- Marino Garcia
- Employees
- 92
- Beta
- 0.09
Explore
Frequently asked questions
What is the intrinsic value of Dianthus Therapeutics, Inc. (DNTH)?
Dianthus Therapeutics, Inc. (DNTH) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is DNTH undervalued?
DNTH trades at a price of $84.55 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.